2024-10-17 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

**1.  Rate Comparison:**

*   MRK's cumulative return: **73.28%**
*   S&P 500 (VOO) cumulative return: **135.94%**
*   **Relative Deviation:** **-62.66%** (S&P 500 outperforms MRK by ~62.66%)
*   **Relative Deviation Rank:** **22.06%** (Currently in the 22.06% percentile of its historical deviation range)

**2. Recent Price Movement:**

*   **Closing Price:** 111.53
*   **5-day Moving Average:** 110.14
*   **20-day Moving Average:** 112.68
*   **60-day Moving Average:** 115.32
*   **Current Trend:** Slightly below 5-day moving average, indicating potential downward pressure. 20-day and 60-day averages suggest a broader trend of declining prices.

**3. Technical Indicators:**

*   **RSI (Relative Strength Index):** 38.92 -  The stock is currently in oversold territory, suggesting potential for a rebound.
*   **PPO (Percentage Price Oscillator):** -0.05 - A negative PPO indicates downward price momentum, but at a relatively low level, which could suggest a potential shift towards sideways or even upward movement.
*   **Delta_Previous_Relative_Divergence:** -15.85 (Negative value) - This indicates a short-term downward trend in the relative divergence, indicating a potential for the stock to continue its downward trajectory.
*   **Expected Return:** 0.0% - This suggests a low potential for exceeding S&P 500 performance in the next 5 years.

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue       |
| :---------- | :----- | :------------ |
| 2024-08-05 | 2.15   | 16.11 B$      |
| 2024-05-03 | 1.88   | 15.78 B$      |
| 2023-11-03 | 1.87   | 15.96 B$      |
| 2023-08-07 | -2.35  | 15.04 B$      |
| 2024-08-05 | -2.35  | 15.04 B$      |

*   **Most recent earnings:** The most recent earnings (2024-08-05) report shows an EPS of 2.15, which is above the analyst expectation of 1.90. Revenue also exceeded expectations, coming in at 16.11 B$ compared to the expected 15.50 B$. This positive earnings beat might contribute to a potential price rebound.
*   **Outlook:** Despite the recent earnings beat, the outlook for MRK remains relatively uncertain.  The pharmaceutical industry is facing several headwinds, including increasing competition, rising drug prices, and regulatory scrutiny.
*   **Analyst Opinions and Performance Highlights:** (Sources like FINBOLD can be used for further analysis of the stock)

**5. News and Current Events:**

*   **Recent Market Outlook:** (Use FINBOLD or similar resources to find relevant news and market outlook for MRK)
*   **Analyst Opinions:** (Gather information on recent analyst ratings, price targets, and recommendations for MRK.)
*   **Performance Highlights:** (Explore significant recent developments, partnerships, or acquisitions related to MRK.)

**6. Comprehensive Analysis:**

MRK's recent performance has been lagging behind the S&P 500, and the stock is currently facing downward price pressure. While the recent earnings beat might offer some potential for a rebound, the overall outlook for the pharmaceutical industry remains uncertain. The RSI suggests potential for a bounce back, but the PPO indicates downward momentum.  With a low expected return, investors should consider the long-term outlook for MRK's products and the overall pharmaceutical market before making any investment decisions.

**7. Conclusion:**

Overall, MRK presents a mixed picture. While the recent earnings beat is a positive development, the stock is currently underperforming the broader market, and the outlook for the pharmaceutical industry is uncertain. Investors should conduct thorough research and consider their risk tolerance before investing in MRK. 
